Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes
| Status: | Completed |
|---|---|
| Conditions: | Diabetes, Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 78 |
| Updated: | 3/2/2017 |
| Start Date: | November 2004 |
| End Date: | May 2006 |
Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a
single oral drug. This is a 28-week extension to a study to assess the safety and
effectiveness of vildagliptin, an unapproved drug, in lowering overall blood glucose levels
when added to metformin in people with type 2 diabetes who are not at target blood glucose
levels on metformin alone. The purpose of the extension study is to gather data on the
long-term safety and effectiveness of vildagliptin in people with type 2 diabetes.
single oral drug. This is a 28-week extension to a study to assess the safety and
effectiveness of vildagliptin, an unapproved drug, in lowering overall blood glucose levels
when added to metformin in people with type 2 diabetes who are not at target blood glucose
levels on metformin alone. The purpose of the extension study is to gather data on the
long-term safety and effectiveness of vildagliptin in people with type 2 diabetes.
Inclusion Criteria:
- Only patients successfully completing study CLAF237A2303 are eligible
- Written informed consent
- Ability to comply with all study requirements
Exclusion Criteria:
- Premature discontinuation from CLAF237A2303
- Other protocol-defined exclusion criteria may apply
We found this trial at
1
site
Click here to add this to my saved trials
